6,8-二溴-3-丁酰基-2H-苯并吡喃-2-酮 | 3855-85-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: 6,8-二溴-3-丁酰基-2H-苯并吡喃-2-酮
• 英文名称: 6,8-Dibrom-coumaryl-3-propylketon
• 英文别名: 6,8-dibromo-3-butyryl-coumarin；6,8-Dibrom-3-butyryl-cumarin；6,8-dibromo-3-butyryl-2H-chromen-2-one；6,8-dibromo-3-butanoylchromen-2-one
• CAS: 3855-85-4
• 化学式: C₁₃H₁₀Br₂O₃
• mdl: MFCD00052895
• 分子量: 374.029
• InChiKey: JOMXLHCIWLDDIM-UHFFFAOYSA-N

物化性质

• 熔点：
  200 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932209090

反应信息

• 作为产物：
  描述：

  3,5-二溴水杨醛 、 丁酰乙酸乙酯 在 哌啶 作用下， 生成 6,8-二溴-3-丁酰基-2H-苯并吡喃-2-酮
  参考文献：
  名称：

  Buu-Hoi et al., Bulletin de la Societe Chimique de France, 1957, p. 561

  摘要：

  DOI：

文献信息

• POLYPEPTIDES AND THEIR USE
  申请人：Novabiotics Limited

  公开号：EP2825261A1

  公开（公告）日：2015-01-21
• USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY
  申请人：Stewart Colin

  公开号：US20100267653A1

  公开（公告）日：2010-10-21

  The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.
• Polypeptides and Their Use
  申请人：O'NEIL Deborah

  公开号：US20140155321A1

  公开（公告）日：2014-06-05

  The present invention relates to a polypeptide or a product comprising said polypeptide for use in the treatment and/or prevention of a fungal infection caused by Malassezia spp. and/or a Malassezia spp associated condition wherein the polypeptide comprises a sequence of about 25 to 200 amino acids wherein substantially all of the amino acids in said sequence are lysine; pharmaceutical compositions comprising said polypeptide or product and uses thereof.
• [EN] POLYPEPTIDES AND THEIR USE<br/>[FR] POLYPEPTIDES ET LEUR UTILISATION
  申请人：NOVABIOTICS LTD

  公开号：WO2013136040A1

  公开（公告）日：2013-09-19

  The present invention relates to a polypeptide or a product comprising said polypeptide for use in the treatment and/or prevention of a fungal infection caused by Malassezia spp. and/or a Malassezia spp associated condition wherein the polypeptide comprises a sequence of about 25 to 200 amino acids wherein substantially all of the amino acids in said sequence are lysine; pharmaceutical compositions comprising said polypeptide or product and uses thereof.